Prelude Therapeutics IncPRLDEarnings & Financial Report
Nasdaq
PRLD Q3 2025 Key Financial Metrics
Revenue
$6.5M
Gross Profit
N/A
Operating Profit
$-20.4M
Net Profit
$-19.7M
Gross Margin
N/A
Operating Margin
-314.1%
Net Margin
-303.5%
YoY Growth
116.7%
EPS
$-0.26
Financial Flow
Prelude Therapeutics Inc Q3 2025 Financial Summary
Prelude Therapeutics Inc reported revenue of $6.5M for Q3 2025, with a net profit of $-19.7M (-303.5% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $6.5M |
|---|---|
| Net Profit | $-19.7M |
| Gross Margin | N/A |
| Operating Margin | -314.1% |
| Report Period | Q3 2025 |
Income Statement
| Q3 2024 | Q3 2025 | |
|---|---|---|
| Revenue | $3.0M | $6.5M |
| YoY Growth | N/A | 116.7% |
Balance Sheet
| Q3 2024 | Q3 2025 | |
|---|---|---|
| Assets | $197.2M | $94.8M |
| Liabilities | $40.8M | $36.2M |
| Equity | $156.4M | $58.5M |
Cash Flow
| Q3 2024 | Q3 2025 | |
|---|---|---|
| Operating CF | $-27.3M | $-19.1M |